Company intelligence / Profile preview

Artugen Therapeutics

Ireland

Ownership: Private
Development stage: Other

Overview

Artugen's lead program BT-051 is in Phase 1 for ulcerative colitis targeting ABCC2 and FPR1, while ART12 is in preclinical for neuroinflammation, ADS032 is in discovery targeting NLRP1 and NLRP3 for respiratory inflammation/infection, and ART24 is pending for Clostridium infections[5].

Therapeutic areas: NeurologyInfectious DiseasesPulmonologyGastroenterology
Modalities: Small moleculeMicrobial therapyLive biotherapeutic product therapy
Industry: Biotech

Beyond the preview

Go deeper on Artugen Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artugen Therapeutics.

Explore the full profile